Separately, HC Wainwright decreased their price target on shares of Aethlon Medical from $90.00 to $23.00 and set a buy rating on the stock in a research note on Tuesday, October 24th.
Aethlon Medical Price Performance
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last posted its quarterly earnings results on Tuesday, November 14th. The medical equipment provider reported ($1.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.13. On average, equities analysts predict that Aethlon Medical will post -5.34 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aethlon Medical
A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Aethlon Medical by 112.9% during the third quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock worth $613,000 after buying an additional 558,596 shares in the last quarter. Renaissance Technologies LLC grew its stake in Aethlon Medical by 11.6% during the first quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock worth $395,000 after buying an additional 28,097 shares in the last quarter. Jane Street Group LLC grew its stake in Aethlon Medical by 895.7% during the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 126,160 shares in the last quarter. Two Sigma Investments LP grew its stake in Aethlon Medical by 219.3% during the first quarter. Two Sigma Investments LP now owns 127,341 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 87,458 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Aethlon Medical during the third quarter worth about $72,000. 3.02% of the stock is currently owned by institutional investors and hedge funds.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.
- Five stocks we like better than Aethlon Medical
- Investing in Commodities: What Are They? How to Invest in Them
- MarketBeat Week in Review – 2/5 – 2/9
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Cloudflare results spark analysts reset: 25% upside ahead
- How to Invest in Mining Stocks
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.